| Assessment Status | Rapid Review Complete |
| HTA ID | 23037 |
| Drug | Beclometasone /formoterol |
| Brand | Fostair® |
| Indication | Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. |
| Assessment Process | |
| Rapid review commissioned | 10/07/2023 |
| Rapid review completed | 20/07/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Fostair® for this indication not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
